Biosimilars have the potential to save the health care system $54 billion over the next ten years and offer access for needed treatments to over 1.2 million patients.

WHAT YOU NEED TO KNOW ABOUT BIOSIMILARS
Stay informed about biosimilars so you can spot misinformation.

FACT
FDA-approved biosimilars have highly similar quality, safety and efficacy to existing biologic medicines.

FACT
There is no clinically meaningful difference between a biosimilar and its reference product.

FACT
It’s safe to switch from a biologic to a biosimilar.

WHAT ARE BIOLOGICS?
Biologic medicines (or reference products) are large-molecule products that involve complex research, development and manufacturing processes. They are often expensive, limiting access for many patients.

WHAT ARE BIOSIMILARS?
Biosimilars are FDA-approved alternatives to reference biologics - much like generic drugs - that provide treatment options for patients who need biologic medicines to manage their conditions.

THE NAME GAME
The FDA provides this valuable resource to help prevent naming confusion between a biosimilar and its biologic counterpart to make sure patients receive the correct treatment option.

Demand Change
- Tear down the barriers preventing patient access to biosimilars.
- Reduce patient out-of-pocket costs for biosimilars.
- Increase reimbursement for lower-cost biosimilars to incentivize education and prescribing.
- Create a biosimilar tier in Medicare Part D with lower cost-sharing for patients.

Wider access to biosimilars benefits patients, doctors and payers. Let’s increase access to biosimilars.

Learn more about biosimilars: biosimilarscouncil.org/advocacy